Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases by targeting Natural Killer T (NKT) cells [4] - The company's lead program, GRI-0621, is an inhibitor of iNKT cell activity being developed as an oral therapeutic for idiopathic pulmonary fibrosis [4] - GRI Bio is also developing a pipeline of novel type 2 NKT agonists for systemic lupus erythematosus [4] - The company has a library of over 500 proprietary compounds to fuel its pipeline [4] Upcoming Events - Marc Hertz, PhD, CEO of GRI Bio, will present at the H C Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 in New York, NY [1] - Management will be available for one-on-one meetings with qualified investors during the conference [2] - A video webcast of the presentation will be available on-demand starting September 9, 2024 at 7:00 AM ET on the company's website and will be archived for 90 days [3] Technology and Pipeline - GRI Bio's therapies target NKT cells, which are key regulators in the inflammatory cascade, to interrupt disease progression and restore immune system homeostasis [4] - Type 1 invariant (iNKT) cells play a critical role in propagating injury, inflammatory response, and fibrosis in inflammatory and fibrotic diseases [4] - The company's approach aims to fundamentally change the treatment of inflammatory, fibrotic, and autoimmune diseases [4]

LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for a poster presentation at the 2024 European Respiratory Congress (ERS) being held September 7-11, 2024 in Vienna, Austria. Details of the poster presentation are as follows: Title: T ...

Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and topline data on track for Q1 2025 LA JOLLA, CA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today repo ...

ST HELIER, Jersey, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("Caledonia" or "the Company") (NYSE AMERICAN, AIM and VFEX: CMCL) announces the publication of its 2023 ESG Report. The full report is available on the Company's website at www.caledoniamining.com/esg/esg-reports/. Caledonia has enhanced its sustainability reporting to align with the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) standards for the first time. This reflects the Compa ...

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (gribio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days. LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fib ...

LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024 at 12:00 PM ET. About GRI Bio, Inc. Live video webcast on Wednesday, July 17th at 12:00 PM ET A live video webcast of the p ...

Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) About GRI Bio, Inc. As part of this "What This Means" segment, Marc Hertz, PhD, Chief Executive Officer of GRI Bio discusses the interim data and what this means for its ongoing IPF program, GRI-0621. Watch the "What This Means" video here. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fi ...

Core Insights - GRI Bio, Inc. emphasizes the significance of interim data from its ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) [1][4] - The company is focused on developing Natural Killer T (NKT) cell modulators to treat inflammatory, fibrotic, and autoimmune diseases [4][6] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company aiming to transform the treatment of inflammatory, fibrotic, and autoimmune diseases [6] - The company's lead program, GRI-0621, is an oral therapeutic designed to inhibit iNKT cell activity for treating IPF, a disease with significant unmet medical needs [6] - GRI Bio is also developing a pipeline of novel type 2 NKT agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its growing pipeline [6]

LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it received notice on July 2, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") that the Company regained compliance with all applicable Nasdaq listing standards for continued listing on the Nasdaq Capital Market, and ...

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar express ...